1. ALLA AKTIER
  2. NYHETER
  3. SURGICAL SCIENCE SWEDEN

Surgical Science Sweden

Nyheter Surgical Science Sweden Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Interim report January-March 2022: A STRONG START TO THE YEAR

MAR

FIRST QUARTER 2022 (JAN – MAR)

Net sales amounted to SEK 159.1 million (37.2), corresponding to an increase of 328 percent compared with the corresponding period in the preceding year.

Simbionix is included in the amount of SEK 115.2 million. For comparable units, sales increased by 32 percent.

Operating profit amounted to SEK 20.0 million (2.2).

Net profit amounted to SEK 16.5 million (1.5), corresponding to earnings per share of SEK 0.32 (0.04).

Cash flow from operating activities amounted to an inflow of SEK 11.1 million (outflow 8.9). As of March 31, 2022, cash and cash equivalents amounted to SEK 329.9 million (263.7).

Gothenburg, Sweden, May 11, 2022
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the clinical environment. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science has more than 200 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and Seattle, US. Through sales offices in the US, France and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: certifiedadviser@penser.se).

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-11 07:30 CEST.

Attachments

220511 Q12022 ENG

Datum 2022-05-11, kl 07:30
Källa MFN
Bifogade filer
220511 Q12022 ENG